Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release
  1. May 08, 2026

    Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — May 8, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical c...

    View more
  2. May 08, 2026

    Harbour BioMed Invests in Windward Bio’s $165M Financing to Advance Pipeline of Long-Acting Immunology Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — May 7, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  3. April 16, 2026

    Harbour BioMed Appoints Dr. Adam Zong as President

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — April 16, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutica...

    View more
  4. March 30, 2026

    Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 30, 2026   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a...

    View more
  5. March 23, 2026

    Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 22, 2026   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutica...

    View more
  6. March 19, 2026

    Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 19, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutica...

    View more
  7. March 09, 2026

    Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

    Cambridge, MA, Rotterdam, NL, Shanghai, CN —March 9, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the ...

    View more
  8. February 23, 2026

    Harbour BioMed Announces License Agreement and Equity Partnership for a Clinical Stage Antibody

    Cambridge, MA, Rotterdam, NL, Shanghai, CN —February 22, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to ...

    View more
  9. February 04, 2026

    Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 3, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  10. January 19, 2026

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 18, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to ...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG